The Cardiometabolic Connection: Why Heart Disease Is a Systems Problem (and How to Treat It That Way)

For Humann Pro practitioners: Cardiovascular disease is often treated as an organ problem—and sometimes as a “numbers” problem (LDL-C, BP, A1c). But the cardiovascular system is also the body’s delivery network for oxygen, nutrients, hormones, immune traffic, and waste removal. When that network degrades, dysfunction can show up everywhere: brain, kidneys, eyes, mitochondria, and metabolic regulation.

• Reframe heart disease as a whole-body vascular and metabolic systems condition.
• Understand why “normal” numbers can miss risk—and when to go deeper.
• Connect mechanisms to practice: endothelium, glycocalyx, nitric oxide, oxidative stress.
• Use practical scripts and takeaways for patient conversations and care planning.

 

The thesis: vascular function is upstream of whole-body function

It’s easy for “cardiovascular health” to collapse into a narrow set of endpoints (MI, stroke) or metrics (BP and a standard lipid panel). But as Christopher Davis, MD, FACC (Chief Cardiologist, Humann) puts it, “Cardiometabolic health is the root of health in general. Your cardiovascular health impacts so many different functions in the body.”

 

The cardiovascular–metabolic connection: supply, demand, and cellular energy

The metabolic system governs how the body processes fuel, regulates glucose/insulin signaling, and produces usable energy. The cardiovascular system governs delivery—whether oxygen, nutrients, and signaling molecules reach tissues at the right time and in the right amounts. In real patients, these aren’t separate lanes; they behave like a coupled network.

 

Regenerative Medicine Pioneer and Humann Science Advisory Board Member, Joseph Purita, MD frames it with a supply-chain analogy that lands in day-to-day practice, “The metabolic system, the cardiovascular system—they’re all related as a supply chain. And if you have a problem in one entity, you’re going to have a problem all downstream.” In other words, metabolic dysfunction and vascular dysfunction amplify each other; you rarely fix one sustainably without addressing the other.

 

• Transport is part of metabolism. Energy production is only half the story; distribution matters. Purita said, “You have to make energy and you have to get that energy transported.”
• Oxygen delivery is a metabolic determinant. If oxygen delivery can’t meet demand, mitochondrial ATP production drops—patients experience this as fatigue, reduced exercise tolerance, and “accelerated aging,” even without classic cardiac symptoms.
• Symptoms can be systemic before they’re diagnostic. Subtle complaints (fatigue, low stamina) can reflect impaired blood supply long before a stress test or angiogram becomes “abnormal.”

 

Why “numbers” aren’t enough: cardiometabolic risk is often missed

Standard screening helps—but “normal” results can coexist with deteriorating vascular biology. Two common ways risk gets missed in practice: (1) hypertension stays silent until end-organ damage is underway, and (2) a basic lipid panel can create false reassurance.

 

Blood pressure: Davis emphasizes that high blood pressure often “feels” like nothing: “People don’t feel bad, even when they have high blood pressure.” That absence of symptoms isn’t reassuring—it’s why elevated readings can quietly damage kidneys, eyes, and the heart. He also cautions against culturally “normalizing” elevated values in clinic workflows.

 

Lipids and risk stratification: A standard lipid panel is not a complete risk model. Davis is blunt: “LDL, HDL and triglyceride numbers don’t really give me a great idea what my cardiovascular risk is.” When the story doesn’t fit—family history, body composition, inflammatory disease, symptom burden—consider advanced lipids (including particle metrics) and inflammation markers to individualize risk.

 

Humann Medical Director, Dr. Yousef Elyaman, MD, IFMCP echoes the need for deeper context than “BP + basic lipids.” He highlights ApoB as a practical example, “We look at something called ApoB that most people don’t even look at, although according to guidelines, they should.” The larger mindset shift: “Move away from thinking of the cardiovascular system as just numbers and as a total measure of vitality and health.”

 

Mechanisms that link cardiometabolic dysfunction

 

Endothelium as the interface

 

Elyaman describes the endothelium as the body’s interface between circulation and tissue biology. “The endothelium is the interface of the cardiovascular system and the rest of the body.” A useful scale reminder: “If you spread out the endothelium, it would be the size of two double-wide tennis courts.” Practically, cardiometabolic disease is often a distributed surface-area problem long before it becomes a focal stenosis problem.

 

 

The glycocalyx: an overlooked layer with outsized consequences

 

On top of the endothelium sits the glycocalyx—an increasingly discussed layer in vascular biology that’s still under-recognized in day-to-day care. Elyaman notes: “The glycocalyx is probably one of the most overlooked areas of the body.” One reason is pragmatic: we tend to prioritize interventions with easy metrics, and tools to assess the glycocalyx are relatively new.

 

Davis connects the dots, “We all know about endothelial dysfunction, but what actually protects the endothelium? It’s the glycocalyx.” Clinical takeaway: when you see early cardiometabolic drift, consider that “vascular health” may reflect barrier integrity and signaling—not just lumen narrowing.

 

Nitric oxide: a multi-system signaling node (not just vasodilation)

 

Nitric oxide (NO) is often remembered as “just” a vasodilator. But Davis emphasizes it as a multi-system signaling molecule. “Nitric oxide is a very important signaling molecule, important in our cardiovascular system, in our neurologic system, in our renal system and immune system.” Practically, when NO signaling is disrupted (aging, oxidative stress, inflammation, oral microbiome disruption), downstream effects can look like impaired exercise tolerance, higher BP, cognitive fog, and reduced metabolic flexibility—without classic angina.

 

Purita reinforces the point: NO is “certainly so many more things” than vasodilation—so treating it like a single-function pathway underserves patients with multi-system symptoms.

 

Oxidative stress as a shared driver

 

Oxidative stress is common ground between cardiology, endocrinology, and functional medicine because it can impair vascular function, mitochondrial efficiency, and cellular signaling at once. Davis uses a sticky patient-facing line, “Oxidative stress is getting rusty inside.” For practitioners, the clinical point is convergence: oxidative stress can worsen endothelial function, reduce NO bioavailability, and increase “metabolic noise” that presents as insulin resistance, fatigue, and inflammatory phenotypes.

 

 

Key takeaways for practice

 

The “systems” reframe only matters if it changes what you do on Monday morning. Here are practice-friendly moves that align with the clinician perspectives above.

 

• Screen for “soft” cardiometabolic symptoms—and treat them as data. Fatigue, reduced stamina, brain fog, and declining exercise capacity can be delivery problems as much as they are sleep, mood, or micronutrient issues. Davis said, “Oftentimes the symptoms are very subtle. But not being able to deliver enough blood supply can cause you to feel that fatigue.”
• Don’t let silent hypertension stay silent. If patients feel fine, they may discount the risk. “People don’t feel bad, even when they have high blood pressure,” Davis said. Pair accurate measurement with tight follow-up and adherence support—because end-organ damage doesn’t require symptoms.
• Risk-stratify beyond the basics when the story doesn’t fit. “Normal labs” aren’t the same as low risk. “We need to look at advanced lipid panels, particle sizes and inflammation markers to truly get a risk assessment for each individual,” Davis said. Consider adding ApoB and other advanced markers when family history, symptoms, or body composition raise suspicion.
• Re-center lifestyle as vascular therapeutics. Nutrition, movement, sleep, and stress aren’t “adjuncts”—they’re upstream levers that affect endothelial function and metabolic regulation. Davis often tells patients, “We need to focus on our nutrition, we must move, sleep and balance our stress load. Stress is an incredible risk factor for heart disease.”

 

How to explain it to patients: “your vessels are the delivery network”

 

When patient engagement stalls, a simple model helps. Purita calls the circulatory system a “superhighway,” and the supply-chain idea is intuitive: bottlenecks upstream create problems downstream. Davis ties it to oxygen delivery and longevity: “Vascular health is everything,” and reminds us of the saying by the “English Hippocrates,” Thomas Sydenham, “A man is only as old as his arteries.” Used carefully, these metaphors help patients understand why cardiometabolic care isn’t “just preventing a heart attack”—it’s protecting how they feel and function day to day.

 

• One-liner: “Your heart and blood vessels are the delivery network for every organ—when delivery slows down, you feel it everywhere.”
• Connect symptoms to physiology: “Fatigue and low stamina can be early signs that tissues aren’t getting the oxygen and nutrients they need.”
• Connect metrics to meaning: “We’re not chasing numbers—we’re using them to estimate your long-term organ health and vitality.”
• Set expectations: “The goal is upstream work—nutrition, movement, sleep, stress—plus the right labs, so we can personalize your plan.”

Conclusion

Heart disease is not solely a cardiac endpoint; it’s often the visible outcome of a system that has been failing quietly across vascular, metabolic, and inflammatory pathways. The opportunity in cardiometabolic care is to measure smarter, intervene earlier, and treat upstream—where endothelial function, oxidative stress, sleep, activity, and nutrition converge. As Elyaman summarizes, “Your cardiovascular system is connected to every cell of your body. If your cardiovascular system is healthy, the rest of your body is healthy.”

 

Sources & attributions

Quoted clinician transcripts (internal): Christopher Davis, MD, FACC (Humann) — DAVIS A4M Transcript Solo.docx; Joseph Purita, MD - Purita transcript log 2025.docx; Yousef Elyaman, MD — Elyaman LOG A4M solo 2025.docx.